Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...

Pfizer not only beat expectations last quarter, but also boosted its guidance.

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

The greater a company's earnings, the better its position will be to pay dividends. However, Pfizer's adjusted earnings per share (EPS) declined 18% year over year in Q3. That might seem to indicate ...

Pfizer’s pricing deal with the Trump administration, which won the company a three-year exemption from sector-specific ...

Pfizer (NYSE:PFE) stock rose 0.6% after the U.S. pharma giant clinched a $10 billion deal for obesity drug developer Metsera, ...

Metsera shares fell significantly as the firm accepted a $10 billion offer from Pfizer, ending its bidding war with Novo Nordisk. Despite the dip, Metsera shares have surged since Pfizer's initial ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors ...

Pfizer has long been a solid dividend payer, having raised its dividend annually for 16 years. Its yield is high because the stock price has fallen in recent years. That has given it an appealing ...

Pfizer Inc. (NYSE:PFE) is one of the stocks highlighted as Jim Cramer responded to questions from Harvard Business School ...

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million ...